The need for customized cell enumeration and vector copy number (VCN) assays is growing as cell therapies become ever more diverse. https://bit.ly/3W4Pdqw But what does this mean for clinical testing, and how do developers ensure comprehensive characterization of cell therapies without significant impacts to their costs and timelines? Read our latest blog to learn more. #CellCarta #PrecisionMedicine #CellTherapy #ClinicalTesting #CellEnumeration #VCN
About us
As a global leader in precision medicine testing services, we partner with our clients to address the most complex biomarker and bioanalytical challenges and deliver highly customized testing solutions. With facilities located in Canada, United States, Belgium, Australia and China, CellCarta provides the expertise needed locally to support global clinical trials. CellCarta offers access to integrated analytical platforms in immunology (immune monitoring), histopathology, proteomics and genomics, as well as digital pathology/AI and sample management, logistics and kitting services. At CellCarta we are experts at assessing the immune system, whether in the context of oncology, infectious diseases, or autoimmune diseases. With a proven track record in other therapeutic areas as, such as neurological and metabolic disorders, we handle all human biological specimens and deploy relevant technologies to extract valuable information for research and diagnostic applications. We provide assay development and testing services to support a wide variety of translational research, clinical trials, and diagnostic applications. Reflecting our commitment to quality, our sites hold the appropriate accreditations to support your regulatory requirements, including CAP, CLIA, ISO15189, ISO27001 and ISO13485.
- Website
-
https://cellcarta.com/
External link for CellCarta
- Industry
- Biotechnology Research
- Company size
- 501-1,000 employees
- Headquarters
- Montreal, Quebec
- Type
- Privately Held
- Specialties
- CRO Laboratory, Oncology, Auto-Immune Diseases, Infectious Diseases, Neurological and Metabolic Disorders, Biomarker, Immune Monitoring, Immunology, Histopathology, Immunohistochemistry, Genomics, Proteomics, Bioinformatics, Mass Spectrometry, Flow Cytometry, ELISpot, Neo-Epitope Discovery, Biologics, Mass Cytometry, Sample Logistics, Kitting, Sample Procurement Tissue Analysis, Molecular Techniques, Tumor Profiling, Personalized Medicine, Biotechnology,, Immunofluorescence, Fluorescence in situ hybridization, Genomics, Pathology, and Pharmaceuticals
Locations
Employees at CellCarta
Updates
-
Changing gate positions manually can make your cytometry analysis take orders of magnitude longer. Now, easier and simpler analysis is within reach! Automatic gating tools are available in CellEngine, our cytometry analysis platform. Using machine learning algorithms, it adjusts gate placement to fit sample data, speeding up your analysis. Want to learn more? Read our blog here 👉 https://bit.ly/3syHXs9 #ClinicalTrials #Biomarkers
-
-
Unlock key insights from your clinical studies with our comprehensive digital pathology image analysis workflow. Download it for free today: https://bit.ly/3pITRhz #CellCarta #PrecisionMedicine #DigitalPathology #ImageAnalysis #ClinicalTrials
-
-
The cell therapy landscape is evolving fast. Discover what that means for clinical testing programs in this trends report from industry experts. Download the trends report: https://bit.ly/3Ljh3Kt
-
-
Measuring B-cell aplasia is becoming increasingly important in clinical testing as cell therapies evolve, read more here: https://bit.ly/3W2c9qp We explore how developers are leveraging the synergies of different testing methods to create new complementary strategies – strategies that paint a more detailed picture of how therapies act against B-cells. This is the first of a handful of posts exploring trends across different cell therapy clinical testing areas, so keep your eyes peeled for more! #CellCarta #PrecisionMedicine #CellTherapy #ClinicalTesting #BCellAplasia
-
-
Wondering what makes our pathology team so special? It’s deeply knowledgeable experts like Zheng Yuan, MD, PhD. Dr. Yuan joined CellCarta in 2020, after 12 years as a hospital pathologist (including at the Cancer Hospital Chinese Academy of Medical Sciences), and 6 years in the anatomical pathology lab of a global CRO, where he focused on biomarker detection. Throughout his career, Dr. Yuan has helped evaluate tumor markers for global and local clinical trials, including dozens of companion diagnostic studies, and has become experienced in analyzing and verifying biomarkers across a variety of assay types. Discover more about Dr. Yuan and the rest of our expert pathology team here 👇 https://bit.ly/42zVai0 #Pathology #Biomarkers #ClinicalTrials
-
-
Need Quick Data Reports? Drop your FCS files with CellCarta. Learn more: https://bit.ly/3L3efkD
-
-
Should you use mass cytometry or spectral flow cytometry for your clinical immune monitoring? 🤔 Choosing the right cytometry platform is crucial for optimizing your clinical studies. But how should you go about answering it? What are the key considerations to keep in mind? Hear from our cytometry expert in our latest blog 👉 https://bit.ly/4brRt0G #FlowCytometry #PrecisionMedicine #ClinicalTrials
-
-
The secret to expert qPCR services? ✔️ Flexibility to support any application, with either off-the-shelf assays or expertly designed and validated custom assays ✔️ Extensive sample and platform experience ✔️ Internationally recognized expertise Discover more about our qPCR services today: https://bit.ly/42io4mC #QuantitativePCR #Biomarkers #ClinicalTrials
-
-
Are HGRAC applications hindering your clinical trials in China? They don’t have to. Our blog post helps you through the process — and highlights how working with the right partner can make it simpler. Sidestep HGRAC roadblocks for a smoother clinical trial in China: https://bit.ly/3r8H1tA #ClinicalTrials #PrecisionMedicine
-